Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
NCT ID: NCT02164071
Last Updated: 2019-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
363 participants
OBSERVATIONAL
2012-04-11
2015-07-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment planning must consider several health indices that are useful when it comes to detecting geriatric problems that could affect the patient's treatment experience. The complete comprehensive geriatric evaluation stands out as cornerstone among other validated tools that do not work as isolated instruments; however, its length and complexity may hinder its routine use in clinical practice for decision making.
The purpose of this study is to validate a comprehensive health status assessment scale in elderly patients (≥65 years) with hematological malignancies that, while integrating the essential dimensions of geriatric assessment and, with the same precision as the currently available valid tools, is shorter and easier to apply, so it can be incorporated into the daily practice and that aids in clinical decision making objectively.
If so, this information would help identify patients that could benefit from a specific oncology treatment, thus contributing to developing a targeted intervention plan and to optimizing the cancer results in this patient population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients
NCT04478916
Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients
NCT06654206
Patient-Centered Care for the Older Adult With Hematologic Malignancy
NCT02359838
Assessing Older Patients With Cancer
NCT00416481
Cohort of Patients Over 70 Years of Age With Cancer and / or Hematological Malignancy
NCT03960593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple Myeloma (MM)
Patients with Myltiple Myeloma, symptomatic or asymptomatic
Geriatric Assessment of Health Status Scale administration
Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
Myelodysplastic Syndromes or Acute Myeloid Leukemia
Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
Geriatric Assessment of Health Status Scale administration
Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
Chronic Lymphocytic Leukemia (CLL)
Patients with Chronic Lymphocytic Leukemia
Geriatric Assessment of Health Status Scale administration
Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Geriatric Assessment of Health Status Scale administration
Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Newly diagnosed patients who belong to one of the 3 following groups:
Patients with MDS (any risk grade as per IPSS) or AML Patients with multiple myeloma (symptomatic or not) or Patients with chronic lymphocytic leukemia (including A status) Patients who have granted their informed consent.
Exclusion Criteria
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Luis Garcia, PhD
Role: STUDY_DIRECTOR
Celgene
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Txagorritxu
Vitoria-Gasteiz, Alava, Spain
Hospital Sant Joan de Deu
Espluges de Llobregat, Barcelona, Spain
Hospital Duran I Reynals
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Parc Tauli
Sabadell, Barcelona, Spain
Hospital de Donostia
Donostia / San Sebastian, Guipuzcoa, Spain
Hospital U. Puerta de Hierro
Majadahonda, Madrid, Spain
C.H. Navarra
Pamplona, Navarre, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Hospital Ntra. Sra. La Candelaria
Santa Cruz de Tenerife, Tenerife, Spain
Hospital La Ribera
Alzira, Valencia, Spain
C.H. Universitario A Coruna
A Coruña, , Spain
Hospital Germans Trias i Pujol
Badalona, , Spain
Hospital Vall d'Hebron
Barcelona, , Spain
Hospital Clinic
Barcelona, , Spain
Hospital Virgen de las Nieves
Granada, , Spain
Arnau de Vilanova
Lleida, , Spain
Hospital U. Gregorio Maranon
Madrid, , Spain
Hospital Infanta Leonor
Madrid, , Spain
Hospital de Segovia
Segovia, , Spain
Hospital Virgen del Rocio
Seville, , Spain
Hospital La Fe
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEL-GAH-2011-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.